Volume : 11, Issue : 05, May – 2024
Title:
REVIEW ON THE ROLE OF THE PHARMACIST IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE
Authors :
Gouthami Kadivendi *, Sreyasri Vallabdas *, Dr.D Venkataramana
Abstract :
At any age, including in childhood, there are a variety of risk factors that might lead to cardiovascular disease (CVD). You can put off or even stop the onset of cardiovascular disease risk factors by adopting a healthy lifestyle. By assisting with patient education and counseling, managing drug safety, reviewing, monitoring, and reconciling medications, identifying and controlling specific cardiovascular risk factors (such as blood pressure, blood glucose, and serum lipids), and clinical outcomes, pharmacists may play an important role in primary and secondary prevention of cardiovascular diseases. Research has shown that when pharmacists are involved, patients with heart failure have better management of their hypertension, dyslipidaemia, or diabetes, are more likely to quit smoking, and have fewer hospitalizations. Economic and humanistic outcomes (such as patient happiness, adherence, and knowledge) have scant evidence of efficacy. It would appear that the most contemporary and effective method of providing healthcare is through a multidisciplinary strategy that incorporates medical expertise with that of a pharmacist, specialty nurse, or both, with a stronger emphasis on community pharmacists as opposed to hospital pharmacists. If we want to know how collaborative practice affects cardiovascular disease and how pharmacists may help reduce it, we need more studies that are both quantitative and qualitative. The sensitivity to the intervention of community pharmacists should be the primary focus of such study. It is reasonable to assume that interventions offered in a community setting will have the greatest impact due to the widespread availability of pharmaceutical services.
Cite This Article:
Please cite this article in press Gouthami kadivendi et al., Review On The Role Of The Pharmacist In The Treatment And Prevention Of Cardiovascular Disease., Indo Am. J. P. Sci, 2024; 11 (05).
Number of Downloads : 10
References:
1. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315–81.
2. Swieczkowski D, Merks P, Gruchala M, et al. The role of the pharmacist in the care of patients with cardiovascular diseases. Kardiol Pol 2016;74:1319–26.
3. Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. US pharmacists’ effect as team members on patient care: systematic review and meta-analyses. Med Care 2010;48:923–33.
4. George PP, Molina JA, Cheah J, et al. The evolving role of the community pharmacist in chronic disease management – a literature review. Ann Acad Med Singapore 2010;39:861–7.
5. Tan EC, Stewart K, Elliott RA, et al. Pharmacist services provided in general practice clinics: a systematic review and meta-analysis. Res Social Adm Pharm 2014;10:608–22.
6. Rotta I, Salgado TM, Silva ML, et al. Effectiveness of clinical pharmacy services: an overview of systematic reviews (2000-2010). Int J Clin Pharm 2015;37:687–97.
7. Moullin JC, Sabater-Hernández D, Fernandez-Llimos F, et al. Defining professional pharmacy services in community pharmacy. Res Social Adm Pharm 2013;9:989–95.
8. Sabater-Hernández D, Sabater-Galindo M, Fernandez-Llimos F, et al. A systematic review of evidence-based community pharmacy services aimed at the prevention of cardiovascular disease. J Manag Care Spec Pharm 2016;22:699–713.
9. Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health Med 2003;25:144–53.
10. Santschi V, Chiolero A, Burnand B, et al. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med 2011;171:1441–53.
11. Brown TJ, Todd A, O’Malley CL, et al. Community pharmacy interventions for public health priorities: a systematic review of community pharmacy-delivered smoking, alcohol and weight management interventions. Southampton UK: NIHR Journals Library, 2016.
12. Rotta I, Souza TT, Salgado TM, et al. Characterization of published randomized controlled trials assessing clinical pharmacy services around the world. Res Social Adm Pharm 2017;13:201–8.
13. Machado M, Bajcar J, Guzzo GC, et al. Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Ann Pharmacother 2007;41:1770–81.
14. Morgado MP, Morgado SR, Mendes LC, et al. Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: review and meta-analysis. Am J Health Syst Pharm 2011;68:241–53.
15. Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc 2014;3:e000718.
16. Cheema E, Sutcliffe P, Singer DR. The impact of interventions by pharmacists in community pharmacies on control of hypertension: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol 2014;78:1238–47.
17. Fleming S, Atherton H, McCartney D, et al. Self-screening and non- physician screening for hypertension in communities: a systematic review. Am J Hypertens 2015;28:1316–24.
18. Machado M, Nassor N, Bajcar JM, et al. Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother 2008;42:1195–207.
19. Charrois TL, Zolezzi M, Koshman SL, et al. A systematic review of the evidence for pharmacist care of patients with dyslipidemia. Pharmacotherapy 2012;32:222–33.
20. Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy 2008;28:421–36.
21. Machado M, Bajcar J, Guzzo GC, et al. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother 2007;41:1569–82.
22. Evans CD, Watson E, Eurich DT, et al. Diabetes and cardiovascular disease interventions by community pharmacists: a systematic review. Ann Pharmacother 2011;45:615–28.
23. Cai H, Dai H, Hu Y, et al. Pharmacist care and the management of coronary heart disease: a systematic review of randomized controlled trials. BMC Health Serv Res 2013;13:461.
24. Altowaijri A, Phillips CJ, Fitzsimmons D. A systematic review of the clinical and economic effectiveness of clinical pharmacist intervention in secondary prevention of cardiovascular disease. J Manag Care Pharm 2013;19:408–16.
25. Metra M, Teerlink JR. Heart failure. Lancet 2017;390:1981–95.
26. Ponniah A, Anderson B, Shakib S, et al. Pharmacists’ role in the
post-discharge management of patients with heart failure: a literature review. J Clin Pharm Ther 2007;32:343–52.
27. Koshman SL, Charrois TL, Simpson SH, et al. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med 2008;168:687–94.
28. Davis EM, Packard KA, Jackevicius CA. The pharmacist role in predicting and improving medication adherence in heart failure patients. J Manag Care Spec Pharm 2014;20:741–55.
29. Thomas R, Huntley AL, Mann M, et al. Pharmacist-led interventions to reduce unplanned admissions for older people: a systematic review and meta-analysis of randomised controlled trials. Age Ageing 2014;43:174–87.
30. Cheng JW, Cooke-Ariel H. Pharmacists’ role in the care of patients with heart failure: review and future evolution. J Manag Care Pharm 2014;20:206–13.
31. Kang JE, Han NY, Oh JM, et al. Pharmacist-involved care for patients with heart failure and acute coronary syndrome: a systematic review with qualitative and quantitative meta-analysis. J Clin Pharm Ther 2016;41:145–57.
32. Holland R, Battersby J, Harvey I, et al. Systematic review of multidisciplinary interventions in heart failure. Heart 2005;91:899–906.
33. Carter BL, Rogers M, Daly J, et al. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med 2009;169:1748–55.
34. Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med 2014;47:86–99.
35. Haines SL, DeHart RM, Hess KM, et al. Report of the 2009-2010 professional affairs committee: pharmacist integration in primary care and the role of academic pharmacy. Am J Pharm Educ 2010;74:S5.
36. Dunn SP, Birtcher KK, Beavers CJ, et al. The role of the clinical pharmacist in the care of patients with cardiovascular disease. J Am Coll Cardiol 2015;66:2129–39.
37. Milfred-Laforest SK, Chow SL, Didomenico RJ, et al. Clinical pharmacy services in heart failure: an opinion paper from the heart failure society of america and american college of clinical pharmacy cardiology practice and research network. J Card Fail 2013;19:354–69.
38. Houle SK, Padwal R, Tsuyuki RT. The 2012-2013 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: An update. Can Pharm J 2013;146:146–50.
39. Omboni S, Sala E. The pharmacist and the management of arterial hypertension: the role of blood pressure monitoring and telemonitoring. Expert Rev Cardiovasc Ther 2015;13:209–21.